RecruitingNCT06537726

Breath Analysis for the Detection of Invasive Fungal Infections

Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients


Sponsor

University of Zurich

Enrollment

130 participants

Start Date

Aug 19, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity. With the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a special breath analysis test can detect serious fungal infections (like aspergillosis) in leukemia patients whose immune systems are weakened by chemotherapy. Catching these infections early could prevent life-threatening complications. **You may be eligible if...** - You have a diagnosis of acute leukemia - You are receiving chemotherapy that requires hospitalization for at least 2 weeks - You have, or are expected to develop, a very low white blood cell count (neutropenia) **You may NOT be eligible if...** - You are unable to follow instructions for the breath test - You have a physical condition that prevents using the breath collection device (mouthpiece) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSecondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)

Identify volatile biomarkers of IFI by analyzing the breath metabolome of patients with proven or probable IFI according to the criteria outlined by EORTC/MSG and controls.


Locations(1)

University Hospital of Zurich

Zurich, Canton of Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06537726


Related Trials